ANG
ANG Lifesciences India financials
- Market cap
- ₹35 Cr
Quarterly results
Q1 FY27: revenue down 37.8%, net profit down 110.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33 | 25 | 17 | 25 | 26 −21% | 19 −24% | 24 +40% | 15 −38% |
| EBITDA | 2 | -2 | -1 | 1 | 0 −96% | -3 −25% | 3 +483% | -2 −400% |
| Net profit | -2 | -5 | -2 | -2 | -3 −41% | -5 +8% | -1 +33% | -4 −111% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +21.2% 1Y
1Y: ₹29.64 on 10 Sept 2025 → ₹35.92. High ₹42.83 (25 Jun 2026), low ₹18.42 (30 Mar 2026).
Financials, as filed
Revenue fell 20.3% a year over 2 years, FY24 to FY26. Operating margin narrowed to 0.8%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹146 Cr | ₹93 Cr | ₹93 Cr |
| Operating profit | ₹10 Cr | ₹-2 Cr | ₹1 Cr |
| Operating margin | 6.6% | -2.5% | 0.8% |
| Interest | ₹11 Cr | ₹9 Cr | ₹8 Cr |
| Depreciation | ₹8 Cr | ₹7 Cr | ₹6 Cr |
| Net profit | ₹-10 Cr | ₹-12 Cr | ₹-11 Cr |
| Net margin | -6.9% | -13.4% | -11.9% |
| Cash from operations | ₹-9 Cr | ₹0 Cr | ₹11 Cr |
| Free cash flow | ₹9 Cr | ₹-4 Cr | ₹11 Cr |
| ROCE | 1.0% | -4.0% | -4.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | — | ₹10 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr |
| Reserves | — | ₹73 Cr | ₹73 Cr | ₹63 Cr | ₹46 Cr | ₹40 Cr |
| Borrowings | — | ₹77 Cr | ₹71 Cr | ₹73 Cr | ₹90 Cr | ₹79 Cr |
| Other liabilities | — | ₹130 Cr | ₹119 Cr | ₹92 Cr | ₹94 Cr | ₹77 Cr |
| Total liabilities | — | ₹290 Cr | ₹276 Cr | ₹241 Cr | ₹243 Cr | ₹209 Cr |
| Fixed assets | — | ₹93 Cr | ₹88 Cr | ₹58 Cr | ₹54 Cr | ₹51 Cr |
| Capital work in progress | — | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | — | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | — | ₹198 Cr | ₹188 Cr | ₹183 Cr | ₹189 Cr | ₹158 Cr |
| Total assets | — | ₹290 Cr | ₹276 Cr | ₹241 Cr | ₹243 Cr | ₹209 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Mar 2025. The shareholder count shrank 9% to 5,952.
- Promoters
- 70.6%
- Public
- 29.4%
Since Mar 2025
- Public +0.01 pp
- Promoters 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Jun '23: Promoters 70.6%, Public 29.4%.Sep '23: Promoters 70.6%, Public 29.4%.Dec '23: Promoters 70.6%, Public 29.4%.Mar '24: Promoters 70.6%, Public 29.4%.Jun '24: Promoters 70.6%, Public 29.4%.Sep '24: Promoters 70.6%, Public 29.4%.Dec '24: Promoters 70.6%, Public 29.4%.Mar '25: Promoters 70.6%, Public 29.4%.Jun '25: Promoters 70.6%, Public 29.4%.Sep '25: Promoters 70.6%, Public 29.4%.Dec '25: Promoters 70.6%, Public 29.4%.Mar '26: Promoters 70.6%, Public 29.4%.
Who is on the register
Named in the Mar 2026 filing
Every holder of ANG Lifesciences India Limited above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| Rajesh Gupta | 70.41% | unchanged |
| Saruchi Gupta | 0.19% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse ANG Lifesciences India Limited
Guides on how to read this kind of business and the numbers that matter.